These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2498468)

  • 1. Promising new drugs in the treatment of tuberculosis and mycobacteriosis.
    Casal M; Rodríguez F; Gutierrez J; Ruiz P; Benavente MC; Villalba R; Moreno G
    J Chemother; 1989 Feb; 1(1):39-45. PubMed ID: 2498468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium avium, Mycobacterium fortuitum, and Mycobacterium chelonae to ticarcillin in combination with clavulanic acid.
    Casal MJ; Rodriguez FC; Luna MD; Benavente MC
    Antimicrob Agents Chemother; 1987 Jan; 31(1):132-3. PubMed ID: 3105441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis, M. avium, M. africanum, M. kansasii and BCG strains].
    Thomas L; Naumann P; Crea A
    Immun Infekt; 1986 Nov; 14(6):203-7. PubMed ID: 3100424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of the new macrolide A-56268 against mycobacteria.
    Berlin OG; Young LS; Floyd-Reising SA; Bruckner DA
    Eur J Clin Microbiol; 1987 Aug; 6(4):486-7. PubMed ID: 2959472
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.
    Molina-Torres CA; Ocampo-Candiani J; Rendón A; Pucci MJ; Vera-Cabrera L
    Antimicrob Agents Chemother; 2010 May; 54(5):2188-90. PubMed ID: 20231398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth.
    Wallace RJ; Nash DR; Steele LC; Steingrube V
    J Clin Microbiol; 1986 Dec; 24(6):976-81. PubMed ID: 3097069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nifurtimox Is Ineffective against Drug-Resistant Mycobacteria.
    Ruth MM; Sangen JJN; Wertheim HFL; van Ingen J
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652235
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.
    Texier-Maugein J; Mormède M; Fourche J; Bébéar C
    Eur J Clin Microbiol; 1987 Oct; 6(5):584-6. PubMed ID: 3125050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the BACTEC system for drug susceptibility testing of Mycobacterium tuberculosis, M. kansasii, and M. avium complex.
    Steadham JE; Stall SK; Simmank JL
    Diagn Microbiol Infect Dis; 1985 Jan; 3(1):33-40. PubMed ID: 3917885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative evaluation of the in vitro antimycobacterial activities of six aminoglycoside antibiotics using an agar dilution method.
    Udou T
    J Chemother; 2006 Dec; 18(6):610-6. PubMed ID: 17267338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational resistance as the mechanism of acquired drug resistance to aminoglycosides and antibacterial agents in Mycobacterium fortuitum and Mycobacterium chelonei. Evidence is based on plasmid analysis, mutational frequencies, and aminoglycoside-modifying enzyme assays.
    Wallace RJ; Hull SI; Bobey DG; Price KE; Swenson JM; Steele LC; Christensen L
    Am Rev Respir Dis; 1985 Aug; 132(2):409-16. PubMed ID: 4026065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to augmentin.
    Casal M; Rodriguez F; Benavente M; Luna M
    Eur J Clin Microbiol; 1986 Aug; 5(4):453-4. PubMed ID: 3093225
    [No Abstract]   [Full Text] [Related]  

  • 14. In-vitro susceptibility of mycobacteria to ciprofloxacin.
    Collins CH; Uttley AH
    J Antimicrob Chemother; 1985 Nov; 16(5):575-80. PubMed ID: 2934361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary study of the in vitro activity of irloxacin against mycobacteria.
    Casal M; Gutierrez J; Ruiz P; Moreno G
    Chemotherapy; 1995; 41(3):204-7. PubMed ID: 7656667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.
    Wallace RJ; Swenson JM; Silcox VA; Bullen MG
    J Infect Dis; 1985 Sep; 152(3):500-14. PubMed ID: 3875667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to cefmetazole.
    Casal MJ; Rodriguez FC; Benavente MC
    Antimicrob Agents Chemother; 1985 Feb; 27(2):282-3. PubMed ID: 3857020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactam antibiotics and mycobacteria.
    Finch R
    J Antimicrob Chemother; 1986 Jul; 18(1):6-8. PubMed ID: 3093446
    [No Abstract]   [Full Text] [Related]  

  • 19. In-vitro activity of quinolones and macrolides against mycobacteria.
    Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF
    J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [In-vitro activity of two hybrid synthetic peptides having antimicrobial activity against mycobacteria].
    Zerbini E; Andreu D; Tonarelli G; Sequeira MD
    Rev Argent Microbiol; 2006; 38(4):221-3. PubMed ID: 17370578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.